Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 219

Sort by

Sort Order Select

Journal Articles

Better together: epcoritamab boosts R2 in FL

Umberto Vitolo, Francesca Bonello

Blood (2025) 146 (22): 2617–2619.

https://doi.org/10.1182/blood.2025031236

Published: 2025

Journal Articles

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen, Raul Cordoba, Sylvia Snauwaert, Neta Goldschmidt, Martin Simkovic, Jacob Christensen, Javier Lopez Jimenez, Ohad Benjamini, Toshihiko Oki, Andrew J. Steele, Marie Holst Mørch, Ernestine Tucker, Rebecca Valentin, Alexey Danilov, Umberto Vitolo

Blood (2025) 146 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2025-1015

Published: 2025

Journal Articles

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Blood (2025) 146 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2025-5364

Published: 2025

Journal Articles

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

Umberto Vitolo, Lorenzo Falchi, Sylvia Snauwaert, Fritz Offner, Marcel Nijland, Per-Ola Andersson, Poliana Patah, Isil Altintas, Jennifer Marek, Malene Risum, Yi Hao, Joshua Brody

Blood (2025) 146 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2025-5357

Published: 2025

Journal Articles

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Rita Tavarozzi, Marco Ladetto, Francesca Bonello, Umberto Vitolo, Pier Luigi Zinzani, Angela Ferrari, Beatrice Casadei, Matthew Ku, Luigi Marcheselli, Stefano Luminari

Blood (2025) 146 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2025-7096

Published: 2025

Journal Articles

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Blood (2025) 146 (Supplement 1): 64.

https://doi.org/10.1182/blood-2025-64

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Blood (2025) 146 (Supplement 1): 55.

https://doi.org/10.1182/blood-2025-55

Published: 2025

Journal Articles

Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study

Umberto Vitolo, Lalita Norasetthada, Jae-Cheol Jo, Biyi Shen, Dina Flink, Min Zhu, Soujanya Chandrasekharan, Jingxiao Chen, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Sabela Bobillo-Varela, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5381.

https://doi.org/10.1182/blood-2025-5381

Published: 2025

Journal Articles

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Joshua Brody, David Belada, Daniel Morillo, Régis Costello, Marek Trneny, Sven de Vos, Gerardo Musuraca, Umberto Vitolo, David Lewis, Jacob Christensen, Marcel Nijland, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Jennifer Marek, Liwei Wang, Malene Risum, Raul Cordoba, Judit Jørgensen

Blood (2025) 146 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2025-3736

Published: 2025

Journal Articles

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Joshua D. Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc André, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba

Blood (2025) 145 (15): 1621–1631.

https://doi.org/10.1182/blood.2024026830

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular and Clinical Analysis of Large B-Cell Lymphomas with MYC gene Involvement: Impact of the Co-Occurrence of TP53 Deletion

Francesca Bonello, Enrico Berrino, Mara Panero, Mattia Novo, Alessia Castellino, Federico Itri, Sara Erika Bellomo, Pio Manlio Mirko Frascione, Barbara Botto, Alberto Bragoni, Valentina Fabiola Ilenia Sangiorgio, Delia Rota-Scalabrini, Caterina Marchiò, Anna Sapino, Laura Casorzo, Umberto Vitolo

Blood (2024) 144 (Supplement 1): 6189.

https://doi.org/10.1182/blood-2024-208448

Published: 2024

Journal Articles

PET Radiomics Discriminate Among Different Lymphoma Sub-Types

Stephane Chauvie, Lale Kostakoglu Shields, Luca Guerra, Annibale Versari, Federico Fallanca, Michele Gregianin, Fabrizio Bergesio, Enrica Bergalla, Adriano De Maggi, Denis Sahin, Rexhep Durmo, Umberto Vitolo, Massimo Federico, Andrea Gallamini, Alessandro Rambaldi, Stefano Luminari

Blood (2024) 144 (Supplement 1): 7505.

https://doi.org/10.1182/blood-2024-205170

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton

Blood (2024) 144 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2024-200369

Published: 2024

Journal Articles

Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2024-207210

Published: 2024

Journal Articles

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2023-184718

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba

Blood (2023) 142 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2023-180246

Published: 2023

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

A new frontier for R-CHOP: is two better than one?

Umberto Vitolo, Annalisa Chiappella

Blood (2023) 142 (16): 1331–1332.

https://doi.org/10.1182/blood.2023021521

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Better together: epcoritamab boosts R2 in FL

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Molecular and Clinical Analysis of Large B-Cell Lymphomas with MYC gene Involvement: Impact of the Co-Occurrence of TP53 Deletion

PET Radiomics Discriminate Among Different Lymphoma Sub-Types

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma

Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

A new frontier for R-CHOP: is two better than one?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only